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Introduction {#sec005}
============

Cerebral venous thrombosis (CVT) has been recognized as a rare disease that is primarily defined as thrombosis in cerebral veins, with a reported annual incidence of 3 to 4 cases per 2 million in adults and 7 cases per 1 million in neonates\[[@pone.0203309.ref001]\]. Clinically, CVT has been suggested to be a rare cerebrovascular disease that accounts for 0.5% of all cerebral strokes\[[@pone.0203309.ref002]\]. With the development of novel sensitive imaging techniques and increasing awareness of clinicians for the disease, the prevalence of CVT, as reported in recent studies, may be higher than previously estimated\[[@pone.0203309.ref003]\]. Although the exact cause of CVT remains to be determined, some risk factors for the disease have been proposed, such as surgery, trauma, immobilization, oral contraceptive pills, pregnancy, puerperium, and others. Moreover, recent evidence suggests that genetic factors related to thrombosis, such as Factor V Leiden (FVL), prothrombin G20210A\[[@pone.0203309.ref004]\], and methylenetetrahydrofolate reductase variant C677T may also be involved in the pathogenesis of CVT.

Accumulating evidence suggests that FVL is an important genetic determinant of venous thromboembolism(VTE)\[[@pone.0203309.ref005]\]. Similarly, some studies have indicated FVL plays a considerable role in the occurrence of CVT. However, the results of these studies varied significantly according to different geographical regions. In previously published meta-analyses, Marjot et al\[[@pone.0203309.ref006]\] included 767 CVT cases and 4020 controls and concluded that FVL was significantly associated with CVT. This was further confirmed in a similar study by Lauw et al\[[@pone.0203309.ref007]\], which included 919 CVT cases and 3168 healthy controls. However, a few case-control studies have been published since these meta-analyses, and whether geographical factors contribute to the heterogeneity regarding the association between FVL and CVT remains to be determined. Therefore, in this updated meta-analysis, we aimed to evaluate the overall association between FVL and CVT and also explored whether this association differed according to the geographical origin of the studies.

Methods {#sec006}
=======

Search strategy {#sec007}
---------------

We performed this meta-analysis according to the guidelines of the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) working group ([S1 File](#pone.0203309.s001){ref-type="supplementary-material"})\[[@pone.0203309.ref008]\] and Meta-analysis on Genetic Association Studies([S1 Table](#pone.0203309.s004){ref-type="supplementary-material"}). We systematically searched electronic databases including PubMed, Web of Science, Embase, and Cochrane Center Register of Controlled Trials (CENTRAL) hosted by the Cochrane Library for relevant studies, and the last search was performed on Nov 10, 2017. No restrictions of language or the region of the study were applied. The search terms were (Factor V Leiden OR Factor V OR 1691A OR 1691) AND (cerebral venous thrombosis OR cerebral vein thrombosis OR cerebral sinus thrombosis OR intracranial venous thrombosis OR intracranial vein thrombosis OR intracranial sinus thrombosis). The detailed search strategy was available ([S2 File](#pone.0203309.s002){ref-type="supplementary-material"}). The search was supplemented by comprehensive manual search of the references of the related studies or reviews, conference abstracts, letters to editor, or key review articles.

Inclusion and exclusion criteria {#sec008}
--------------------------------

Studies were included if they met the following eligibility criteria: (1) case-control studies; (2) enrollment of patients with cerebral venous or sinus or cortical vein thrombosis, which was objectively confirmed by accepted imaging methods (computed tomography, magnetic resonance imaging, magnetic resonance venography, magnetic resonance black-blood thrombus imaging, or angiography) or objectively documented by medical records; (3) control participants were non-genetically related subjects without a history of venous thromboembolism; (4) both cases and controls underwent genetic testing for FVL; and (5) the frequencies of FVG1691A for both CVT cases and controls were reported in original studies or could be calculated.

Studies were excluded from the current meta-analysis if they met the following criteria: (1) CVT was neither confirmed by imaging methods or documented by medical files; (2) genetic testing for FVL was not performed for the control group; or (3) data of interest were not available. If two studies with considerable overlapped (\>50%) population were retrieved, the one most recently published study or the study of highest quality was included to avoid publication bias\[[@pone.0203309.ref007]\].

Data extraction {#sec009}
---------------

Two authors (Xinyuan Li and Li Cui) independently assessed the eligible studies and extracted data using standard abstraction forms. Disagreements were resolved by reaching a consensus with a third author. In addition, we attempted to contact the corresponding author to request missing data via E-mail. The following information for each study was collected: the first author's name, year of publication, number of participants, country, study design, age, sex, diagnostic methods of CVT, source of control, and FVL genotype frequencies in case and control groups.

Quality assessment {#sec010}
------------------

Two authors (Xinyuan Li and Yunbo Li) independently evaluated the quality of the included studies according to the Newcastle-Ottawa Scale (NOS) for observational studies\[[@pone.0203309.ref009]\], and disagreements were resolved by reaching a consensus with a third author(Shaokuan Fang). The NOS consists of three main parts: selection (4 stars), comparability (2 stars), and outcome (3 stars) and ranges from 0--9 stars\[[@pone.0203309.ref010]\]. Thus, the quality of each study was determined on a scale from 0--9 points. Studies with 7--9 points were regarded as "high quality", with 4--6 points as "moderate quality", and with less than 4 points as "low quality"\[[@pone.0203309.ref011]\].

Statistical analysis {#sec011}
--------------------

The primary outcome of the present study was defined as the odds ratio(OR) for the prevalence of FVL in patients with CVT as compared with that in healthy controls. We used the Review Manager 5.3 (Cochrane Collaboration, London, UK) and Stata (Version 12.0) software for statistical analyses. The significance of the pooled estimates was determined by Z statistic with 95% confidence interval (CI), and statistical significance was set at a two-tailed P\<0.05. Data were pooled when there were at least three case-control studies. ORs were combined using the Mantel-Haenszel method and a random-effects model that takes into account the variability among the included studies. Study heterogeneity was evaluated by the I^2^ statistic: a value of\<50% indicated low to moderate heterogeneity, ≥50% indicated substantial heterogeneity. In general, significant heterogeneity was defined as I^2^≥50% and P\<0.05. The genotypes of FVL mutation (G1691A) consisted of normal homozygote (G/G), mutated homozygote (A/A), and heterozygote (G/A). We regarded homozygote (A/A) and heterozygote (G/A) carriers of FVL as one group due to the rarity of homozygote carriers (A/A). Thus, a dominant model was applied. We performed a subgroup analysis based on geographical regions of the studies to identify whether this factor contributed to the heterogeneity among the included studies. We were unable to conduct other subgroup analyses (race/ethnicity, education level, family income, and disease severity) owing to studies not providing sufficient stratified data. We used a sensitivity analysis to evaluate the robustness of the results by omitting one study at a time. The publication bias was assessed by the funnel plot and the Egger's test \[[@pone.0203309.ref012]--[@pone.0203309.ref013]\].

Results {#sec012}
=======

Database search {#sec013}
---------------

A total of 651 articles were initially retrieved from the electronic database search (290 from PubMed, 240 from Web of Science, 86 from Embase, and 26 from CENTRAL). Then 369 irrelevant articles, 124 duplicate papers, and 63 reviews were excluded based on screening of the title and abstracts. Among the remaining 47 studies, characteristics of the eight studies\[[@pone.0203309.ref014]--[@pone.0203309.ref021]\] excluded from analysis were presented([S2 Table](#pone.0203309.s005){ref-type="supplementary-material"}). Seven were excluded due to the overlapped population of already included studies, and the other one was excluded because no FVL was detected in cases or controls. Thus, 39 studies([S3 File](#pone.0203309.s003){ref-type="supplementary-material"}) were included in the current meta-analysis. [Fig 1](#pone.0203309.g001){ref-type="fig"} illustrated the flowchart of database search and study identification and [Table 1](#pone.0203309.t001){ref-type="table"} summarized the characteristics of the included studies.

![PRISMA flow diagram.\
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###### Characteristics of the included studies.

![](pone.0203309.t001){#pone.0203309.t001g}

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                    Year   Country       CVT ascertainment                                       CVT(N)   Male/ female (N)   Mean or median age(range), years   Controls (N)   Male/ female (N)   Age               Matched
  ------------------------ ------ ------------- ------------------------------------------------------- -------- ------------------ ---------------------------------- -------------- ------------------ ----------------- --------------------------------------------
  **Zuber**                1996   France        MRI and/or angiography                                  19       4/15               \- (20--72)                        57             \-                 \-                Age

  **Weih**                 1998   Germany       MRA or angiography                                      12       2/10               33.8 (21--60)                      36             6/30               34.2 (-)          Age

  **Junker**               1998   Germany       MRA or DSA                                              58       20/38              32.5 (0.3--73)                     105            50/55              44.0 (10--55)     Ethnical background

  **Hillier**              1998   UK            CT,MRI,MRV or autopsy                                   15       2/13               35.3 (17--76)                      300            \-                 \-                \-

  **Lüdemann**             1998   Germany       MRI and/or DSA                                          55       15/40              40.0 (11--83)                      272            \-                 \- (18--55)       Same region

  **Hagstrom**             1998   US            MRI and/or angiography                                  9        \-                 \-                                 65             \-                 \-                \-

  **Schobess**             1999   Germany       CT, MRI and venography                                  15       \-                 \-                                 100            \-                 \-                Age and sex

  **Madonna**              2000   Italy         MRI and/or\                                             10       4/6                35.1(-)                            259            115/144            36.7              Age,sex and ethnic background
                                                Angiography                                                                                                                                                                

  **Voetsch**              2000   Brazil        CT,MRI and/or angiography                               14       4/10               24 8 (16--31)                      225            99/126             34.1 (16--50)     Age,sex,ethnic background

  **Margaglione**          2001   Italy         Documented objectively.                                 28       13/15              \- (-)                             1304           576/743            36.0 (22--66)     \-

  **Bombeli**              2002   Switzerland   CT,MRI,venography or angiography                        51       14/37              36.7 (17--61)                      120            48/72              37.4 (19--62)     \-

  **Meng**                 2002   China         Angiography                                             20       8/12               31.0 (20--48)                      50             28/22              38.0 (18--58)     \-

  **Martinelli**           2003   Italy         CT,MRI and/or angiography                               121      30/91              33.0 (12--64)                      242            60/182             36.0 (13--62)     Age and sex

  **Heller**               2003   Germany       CT,MRI,MRV or MRA                                       149      84/65              6.0 (0--18)                        149            89/60              6.2 (0--18)       Age and sex

  **Bonduel**              2003   Argentina     CT,MRI and/or MRA                                       23       20/3               \- (0.2--16)                       102            60/42              7.1 (0.2--15.9)   Age

  **Rodrigues**            2004   Brazil        MRI and/or angiography                                  42       14/28              28.0(-)                            134            54/80              34.0(-)           \-

  **Gadelha**              2004   Brazil        MRA or angiography                                      26       5/21               28.5 (3--46)                       217            83/134             29.0 (15--62)     Age,sex and racial background

  **Boncoraglio**          2004   Italy         CT,MRI,MRA or intra-arterial angiography                26       7/19               43.0 (21--73)                      100            49/51              41.5 (21--72)     Ethnic background

  **Ventura**              2004   Italy         CT or angiography                                       30       16/14              35.0 (16--49)                      40             22/18              34.0 (18--51)     Age,sex and ethnic background

  **Kenet**                2004   Israel        Documented objectively and confirmed by a neurologist   38       23/15              5.6(-)                             112            60/52              6.3(-)            Age,gender distribution and ethnic origin

  **Lichy**                2005   Germany       MRI and/or angiography                                  77       17/60              38.0(-)                            203            85/118             36.5(-)           Same region

  **Dindagur**             2006   India         MRI/MRV                                                 86       0/86               23.5 (18--36)                      86             0/86               24.0(-)           Age

  **Miller**               2006   US            CT and/or MRI                                           24       \-                 \-                                 437            \-                 \-                \-

  **Stolz**                2007   Germany       MRI,MRA,CTA or DSA                                      121      28/93              43.5 (18--85)                      120            30/90              43.4 (22--82)     Age,sex and same institution

  **Colaizzo**             2007   Italy         Spiral CT or MRI                                        45       14/31              40.0 (13--55)                      286            119/163            44.0(21--73)      Age,sex and social status

  **Romero**               2007   Spain         CT and/or MRI                                           15       5/10               33.4(-)                            60             \-                 \-                Age and sex

  **Altinisik**            2008   Turkey        Documented objectively                                  31       \-                 \-                                 25             10/15              32.4 (22--47)     \-

  **Le Cam-Duchez**        2008   France        CT,MRI and/or angiography                               54       11/43              37.1(-)                            100            39/61              41.3(-)           \-

  **Koopman**              2009   Netherlands   Digital angiography, CT,MRI or surgery                  19       4/15               36.0 (18--55)                      19             \-                 \-                Age and sex

  **Rahimi**               2010   Iran          MRI                                                     24       7/17               37.1(-)                            100            50/50              36.1(-)           Age,sex and ethnic background

  **Laugesaar**            2010   Estonia       MRV or CTV                                              7        \-                 \-                                 400            207/193            \-                \-

  **Cesarman-Maus**        2011   Mexico        MRI and/or angiography                                  40       7/33               28.2 (14--61)                      145            0/145              36.7 (22--63)     \-

  **Ringelstein**          2012   Germany       MRI and/or angiography                                  136      33/102             41.0 (16--85)                      1054           \-                 -(25--74)         Ethnic background

  **Ben Salem-Berrabah**   2012   Tunisia       CT,MRI,MRV,MRA or autopsy                               26       5/21               38.26 (15--72)                     197            126/71             31.0 (14--54)     \-

  **Ashjazadeh**           2012   Iran          MRI/MRV                                                 57       19/38              33.7(-)                            50             \-                 \-                Age,sex,geographical and ethnic background

  **Orikaza**              2013   Brazil        CT,MRI or angiography                                   72       16/56              32.5 (8--69)                       143            \-                 37.0 (18--66)     Age and sex

  **Klai**                 2013   Tunisia       MRI                                                     51       0/51               30.0(-)                            100            0/100              30.6(-)           Same geographic and socioeconomic group

  **Tufano**               2014   Italy         Documented objectively                                  56       15/41              34.98(-)                           184            50/134             35.05             Age and sex

  **Saadatnia**            2015   Iran          MRI, venography or angiography                          40       \-                 33.45(-)                           51             \-                 30.75             Age and race

  **Beye**                 2017   Germany       CT,MRI and/or DSA                                       101      24/77              38.8 (18--76)                      101            24/77              39.2 (19--70)     Age and sex
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

CVT, cerebral venous thrombosis; CT, computed tomography; MRI, magnetic resonance imaging; MRA, magnetic resonance angiography; MRV, magnetic resonance venography; DSA, digital subtraction angiography; CTA, computed tomography angiography; CTV, computed tomography venography;---,not applicable.

Study characteristics {#sec014}
---------------------

Overall, 39 case-control studies were included in the current analysis, with 1822 cases of CVT and 7795 controls. The included studies were published between 1996 and 2017. Among 39 studies, 14 studies did not report specific genotypes of FVL, 4 studies reported all genotypes including homozygous G1691A polymorphism, and the remaining 21 studies only reported heterozygous polymorphism. Thus, we considered homozygote (A/A) and heterozygote (G/A) carriers of FVL as one group using a dominant model. Additionally, we failed to detect the Hardy-Weinberg equilibrium(HWE) of controls.

Quality assessment {#sec015}
------------------

The quality of included 39 case-control studies assessed by NOS was shown in [Table 2](#pone.0203309.t002){ref-type="table"}. The scores from 4--9 were regarded as moderate and high quality.

10.1371/journal.pone.0203309.t002

###### Details of quality assessment of the included studies.

![](pone.0203309.t002){#pone.0203309.t002g}

  Study                    Year   Is the case definition adequate?       Representativeness of the cases        Selection of controls                  Definition of controls                 Comparability of cases and controls on the basis of the design or analysis   Ascertainment of exposure              Same method of ascertainment for cases and controls   Non- Response rate                     Score                                  
  ------------------------ ------ -------------------------------------- -------------------------------------- -------------------------------------- -------------------------------------- ---------------------------------------------------------------------------- -------------------------------------- ----------------------------------------------------- -------------------------------------- -------------------------------------- ---
  **Zuber**                1996   [★](#t002fn001){ref-type="table-fn"}   [★](#t002fn001){ref-type="table-fn"}   [★](#t002fn001){ref-type="table-fn"}   [★](#t002fn001){ref-type="table-fn"}   [★](#t002fn001){ref-type="table-fn"}                                                                                [★](#t002fn001){ref-type="table-fn"}                  [★](#t002fn001){ref-type="table-fn"}   [★](#t002fn001){ref-type="table-fn"}   8
  **Weih**                 1998   [★](#t002fn001){ref-type="table-fn"}   [★](#t002fn001){ref-type="table-fn"}                                          [★](#t002fn001){ref-type="table-fn"}   [★](#t002fn001){ref-type="table-fn"}                                                                                [★](#t002fn001){ref-type="table-fn"}                  [★](#t002fn001){ref-type="table-fn"}   [★](#t002fn001){ref-type="table-fn"}   7
  **Junker**               1998   [★](#t002fn001){ref-type="table-fn"}                                          [★](#t002fn001){ref-type="table-fn"}                                                                                                                                                              [★](#t002fn001){ref-type="table-fn"}                  [★](#t002fn001){ref-type="table-fn"}   [★](#t002fn001){ref-type="table-fn"}   5
  **Hillier**              1998   [★](#t002fn001){ref-type="table-fn"}   [★](#t002fn001){ref-type="table-fn"}   [★](#t002fn001){ref-type="table-fn"}   [★](#t002fn001){ref-type="table-fn"}                                                                                                                       [★](#t002fn001){ref-type="table-fn"}                  [★](#t002fn001){ref-type="table-fn"}                                          6
  **Lüdemann**             1998   [★](#t002fn001){ref-type="table-fn"}   [★](#t002fn001){ref-type="table-fn"}   [★](#t002fn001){ref-type="table-fn"}                                                                                                                                                              [★](#t002fn001){ref-type="table-fn"}                  [★](#t002fn001){ref-type="table-fn"}   [★](#t002fn001){ref-type="table-fn"}   6
  **Hagstrom**             1998   [★](#t002fn001){ref-type="table-fn"}   [★](#t002fn001){ref-type="table-fn"}                                                                                                                                                                                                     [★](#t002fn001){ref-type="table-fn"}                  [★](#t002fn001){ref-type="table-fn"}   [★](#t002fn001){ref-type="table-fn"}   5
  **Schobess**             1999   [★](#t002fn001){ref-type="table-fn"}   [★](#t002fn001){ref-type="table-fn"}                                                                                 [★](#t002fn001){ref-type="table-fn"}                                                                                                                                      [★](#t002fn001){ref-type="table-fn"}   [★](#t002fn001){ref-type="table-fn"}   5
  **Madonna**              2000   [★](#t002fn001){ref-type="table-fn"}   [★](#t002fn001){ref-type="table-fn"}   [★](#t002fn001){ref-type="table-fn"}   [★](#t002fn001){ref-type="table-fn"}   [★](#t002fn001){ref-type="table-fn"}                                                                                [★](#t002fn001){ref-type="table-fn"}                  [★](#t002fn001){ref-type="table-fn"}   [★](#t002fn001){ref-type="table-fn"}   8
  **Voetsch**              2000   [★](#t002fn001){ref-type="table-fn"}   [★](#t002fn001){ref-type="table-fn"}   [★](#t002fn001){ref-type="table-fn"}   [★](#t002fn001){ref-type="table-fn"}   [★](#t002fn001){ref-type="table-fn"}                                                                                [★](#t002fn001){ref-type="table-fn"}                  [★](#t002fn001){ref-type="table-fn"}   [★](#t002fn001){ref-type="table-fn"}   8
  **Margaglione**          2001                                          [★](#t002fn001){ref-type="table-fn"}   [★](#t002fn001){ref-type="table-fn"}   [★](#t002fn001){ref-type="table-fn"}                                                                                                                       [★](#t002fn001){ref-type="table-fn"}                  [★](#t002fn001){ref-type="table-fn"}   [★](#t002fn001){ref-type="table-fn"}   6
  **Bombeli**              2002   [★](#t002fn001){ref-type="table-fn"}   [★](#t002fn001){ref-type="table-fn"}   [★](#t002fn001){ref-type="table-fn"}   [★](#t002fn001){ref-type="table-fn"}                                                                                                                       [★](#t002fn001){ref-type="table-fn"}                  [★](#t002fn001){ref-type="table-fn"}   [★](#t002fn001){ref-type="table-fn"}   7
  **Martinelli**           2003   [★](#t002fn001){ref-type="table-fn"}   [★](#t002fn001){ref-type="table-fn"}   [★](#t002fn001){ref-type="table-fn"}   [★](#t002fn001){ref-type="table-fn"}   [★](#t002fn001){ref-type="table-fn"}                                         [★](#t002fn001){ref-type="table-fn"}   [★](#t002fn001){ref-type="table-fn"}                  [★](#t002fn001){ref-type="table-fn"}   [★](#t002fn001){ref-type="table-fn"}   9
  **Heller**               2003   [★](#t002fn001){ref-type="table-fn"}   [★](#t002fn001){ref-type="table-fn"}   [★](#t002fn001){ref-type="table-fn"}                                          [★](#t002fn001){ref-type="table-fn"}                                         [★](#t002fn001){ref-type="table-fn"}   [★](#t002fn001){ref-type="table-fn"}                  [★](#t002fn001){ref-type="table-fn"}   [★](#t002fn001){ref-type="table-fn"}   8
  **Bonduel**              2003   [★](#t002fn001){ref-type="table-fn"}   [★](#t002fn001){ref-type="table-fn"}   [★](#t002fn001){ref-type="table-fn"}                                                                                                                                                              [★](#t002fn001){ref-type="table-fn"}                  [★](#t002fn001){ref-type="table-fn"}   [★](#t002fn001){ref-type="table-fn"}   6
  **Rodrigues**            2004   [★](#t002fn001){ref-type="table-fn"}   [★](#t002fn001){ref-type="table-fn"}   [★](#t002fn001){ref-type="table-fn"}   [★](#t002fn001){ref-type="table-fn"}                                                                                                                                                                             [★](#t002fn001){ref-type="table-fn"}   [★](#t002fn001){ref-type="table-fn"}   6
  **Gadelha**              2004   [★](#t002fn001){ref-type="table-fn"}   [★](#t002fn001){ref-type="table-fn"}   [★](#t002fn001){ref-type="table-fn"}   [★](#t002fn001){ref-type="table-fn"}   [★](#t002fn001){ref-type="table-fn"}                                                                                [★](#t002fn001){ref-type="table-fn"}                  [★](#t002fn001){ref-type="table-fn"}   [★](#t002fn001){ref-type="table-fn"}   8
  **Boncoraglio**          2004   [★](#t002fn001){ref-type="table-fn"}   [★](#t002fn001){ref-type="table-fn"}                                                                                                                                                                                                     [★](#t002fn001){ref-type="table-fn"}                  [★](#t002fn001){ref-type="table-fn"}   [★](#t002fn001){ref-type="table-fn"}   5
  **Ventura**              2004   [★](#t002fn001){ref-type="table-fn"}                                          [★](#t002fn001){ref-type="table-fn"}                                          [★](#t002fn001){ref-type="table-fn"}                                                                                [★](#t002fn001){ref-type="table-fn"}                  [★](#t002fn001){ref-type="table-fn"}   [★](#t002fn001){ref-type="table-fn"}   6
  **Kenet**                2004   [★](#t002fn001){ref-type="table-fn"}   [★](#t002fn001){ref-type="table-fn"}   [★](#t002fn001){ref-type="table-fn"}                                                                                                                                                              [★](#t002fn001){ref-type="table-fn"}                  [★](#t002fn001){ref-type="table-fn"}   [★](#t002fn001){ref-type="table-fn"}   6
  **Lichy**                2005   [★](#t002fn001){ref-type="table-fn"}   [★](#t002fn001){ref-type="table-fn"}   [★](#t002fn001){ref-type="table-fn"}   [★](#t002fn001){ref-type="table-fn"}                                                                                                                       [★](#t002fn001){ref-type="table-fn"}                  [★](#t002fn001){ref-type="table-fn"}                                          6
  **Dindagur**             2006   [★](#t002fn001){ref-type="table-fn"}   [★](#t002fn001){ref-type="table-fn"}   [★](#t002fn001){ref-type="table-fn"}   [★](#t002fn001){ref-type="table-fn"}   [★](#t002fn001){ref-type="table-fn"}                                                                                [★](#t002fn001){ref-type="table-fn"}                  [★](#t002fn001){ref-type="table-fn"}   [★](#t002fn001){ref-type="table-fn"}   8
  **Miller**               2006   [★](#t002fn001){ref-type="table-fn"}   [★](#t002fn001){ref-type="table-fn"}   [★](#t002fn001){ref-type="table-fn"}                                                                                                                                                              [★](#t002fn001){ref-type="table-fn"}                  [★](#t002fn001){ref-type="table-fn"}                                          5
  **Stolz**                2007   [★](#t002fn001){ref-type="table-fn"}   [★](#t002fn001){ref-type="table-fn"}   [★](#t002fn001){ref-type="table-fn"}                                          [★](#t002fn001){ref-type="table-fn"}                                                                                [★](#t002fn001){ref-type="table-fn"}                  [★](#t002fn001){ref-type="table-fn"}   [★](#t002fn001){ref-type="table-fn"}   7
  **Calaizzo**             2007   [★](#t002fn001){ref-type="table-fn"}   [★](#t002fn001){ref-type="table-fn"}   [★](#t002fn001){ref-type="table-fn"}   [★](#t002fn001){ref-type="table-fn"}   [★](#t002fn001){ref-type="table-fn"}                                         [★](#t002fn001){ref-type="table-fn"}   [★](#t002fn001){ref-type="table-fn"}                  [★](#t002fn001){ref-type="table-fn"}   [★](#t002fn001){ref-type="table-fn"}   9
  **Romero**               2007   [★](#t002fn001){ref-type="table-fn"}   [★](#t002fn001){ref-type="table-fn"}   [★](#t002fn001){ref-type="table-fn"}   [★](#t002fn001){ref-type="table-fn"}   [★](#t002fn001){ref-type="table-fn"}                                                                                [★](#t002fn001){ref-type="table-fn"}                  [★](#t002fn001){ref-type="table-fn"}   [★](#t002fn001){ref-type="table-fn"}   8
  **Altinisik**            2008                                          [★](#t002fn001){ref-type="table-fn"}                                                                                                                                                                                                     [★](#t002fn001){ref-type="table-fn"}                  [★](#t002fn001){ref-type="table-fn"}   [★](#t002fn001){ref-type="table-fn"}   4
  **Le Cam-Duchez**        2008   [★](#t002fn001){ref-type="table-fn"}   [★](#t002fn001){ref-type="table-fn"}   [★](#t002fn001){ref-type="table-fn"}   [★](#t002fn001){ref-type="table-fn"}   [★](#t002fn001){ref-type="table-fn"}                                                                                [★](#t002fn001){ref-type="table-fn"}                  [★](#t002fn001){ref-type="table-fn"}   [★](#t002fn001){ref-type="table-fn"}   8
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★ evaluates the quality of included studies according to every part of NOS.

Prevalence of FVL in CVT patients versus controls {#sec016}
-------------------------------------------------

Upon combining the data from all available studies, FVL/G1691A was found in 195/1822 CVT cases and 369/7795 controls (OR = 2.70, 95%CI 2.16--3.38, P\<0.00001) ([Fig 2](#pone.0203309.g002){ref-type="fig"}).

![Forest plot of overall prevalence of FVL in CVT patients as compared with controls.\
CI, confidence interval; CVT, cerebral venous thrombosis.](pone.0203309.g002){#pone.0203309.g002}

Subsequently, we performed a subgroup analysis based on region of the studies. The studies were performed in countries including Italy (7 studies), Germany (9 studies), France (2 studies), Brazil (4 studies), Iran (3 studies), Tunisia (2 studies), the US (2 studies), the UK (1 study), Switzerland (1 study), Argentina (1 study), Israel (1 study), India (1 study), Spain (1 study), Turkey (1 study), the Netherlands (1 study), Estonia (1 study), and Mexico (1 study). We performed subgroup analysis according to countries where the at least two studies were performed ([Fig 3](#pone.0203309.g003){ref-type="fig"}). Briefly, in Italy, FVL was found in 24/316 CVT cases and 111/2415 controls, and the prevalence was not significantly different (OR = 1.49, 95%CI 0.59--3.78, P = 0.40, I^2^ = 44%). In Germany, FVL was found in 96/724 CVT cases and 139/2139 controls(OR = 2.42, 95%CI 1.70--3.45, P\<0.00001, I^2^ = 14%). In Brazil, FVL was found in 11/154 CVT cases and 19/719 controls (OR = 2.82, 95%CI 1.24--6.42, P = 0.01, I^2^ = 0%). In France, FVL was found in 9/73 CVT cases and 4/157 controls (OR = 5.44, 95%CI 1.35--21.92, P = 0.02, I^2^ = 17%). In Iran, FVL was found in 10/121 CVT cases and 3/201 controls (OR = 6.61, 95%CI 1.83--23.93, P = 0.004, I^2^ = 0%). In the two studies from Tunisia, the prevalence of FVL was higher in CVT cases than in controls (OR = 6.54, 95%CI 2.89--14.82, P\<0.00001, I^2^ = 0%). In the US, the prevalence of FVL did not significantly differ between the groups (OR = 2.37, 95%CI 0.59--9.42, P = 0.22, I^2^ = 0%).

![Subgroup analysis based on different countries.\
CI, confidence interval; CVT, cerebral venous thrombosis.](pone.0203309.g003){#pone.0203309.g003}

We also performed a subgroup analysis based on CVT ascertainment ([Fig 4](#pone.0203309.g004){ref-type="fig"}) to find the source of heterogeneity and found that the association was not significant between FVL and documented CVT (OR = 0.91, 95%CI 0.39--2.16, P = 0.83) and the prevalence of FVL was higher in cases of CVT diagnosed by specific radiological methods than in healthy controls (OR = 2.86, 95%CI 2.27--3.60, P\<0.00001).

![Subgroup analysis based on CVT ascertainment.\
CVT,cerebral venous thrombosis.](pone.0203309.g004){#pone.0203309.g004}

Publication bias {#sec017}
----------------

There was no possibility of publication bias as indicated by the funnel plot and results of Egger's test (P = 0.135) ([Fig 5](#pone.0203309.g005){ref-type="fig"}).

![Funnel plot of publication bias.](pone.0203309.g005){#pone.0203309.g005}

Sensitivity analysis {#sec018}
--------------------

The results of sensitivity analysis for the prevalence of FVL indicated that the results were not significantly affected by excluding any one of the studies ([Fig 6](#pone.0203309.g006){ref-type="fig"}), suggesting the robustness of the results.

![Sensitivity analysis of the overall prevalence of FVL.\
FVL, Factor V Leiden; CVT, cerebral venous thrombosis.](pone.0203309.g006){#pone.0203309.g006}

Discussion {#sec019}
==========

Although FVL has been established as the most common inherited risk factor for VTE\[[@pone.0203309.ref005],[@pone.0203309.ref022]\], it has been confirmed that the prevalence of FVL in patients with deep vein thrombosis (DVT) and pulmonary embolism varies significantly among different regions and ethnicities\[[@pone.0203309.ref023]--[@pone.0203309.ref026]\]. However, whether the association between FVL and CVT is similar remains to be determined. To assess this issue, we performed a meta-analysis of 39 case-control studies including 1822 cases of CVT and 7795 controls and found that FVL was more common in patients with CVT than in health controls. However, the association between FVL and CVT varied depending on the geographic origin of the studies. To the best of our knowledge, this is the largest comprehensive meta-analysis for the overall prevalence of FVL mutation in patients with CVT. This is also the first evaluation of geographical variation of FVL in patients with CVT.

In general, we found that FVL was significantly associated with CVT, which was consistent with the results of previous reviews\[[@pone.0203309.ref006]--[@pone.0203309.ref007]\]. The current meta-analysis confirmed an overall significant association between FVL and CVT, but this association was highly dependent on the geography of patients. The association was significant between FVL and CVT in studies conducted in Germany, Brazil, France, Iran, and Tunisia, but not in those from Italy or the US. These results were consistent with previous reports that FVL is a contributory risk factor for the development of VTE\[[@pone.0203309.ref027]--[@pone.0203309.ref028]\]. However, it should be noted that the association between FVL and CVT was not statistically significant in Italy, which was inconsistent with the previous literature suggesting the prevalence of FVL in VTE was high in the Italian population\[[@pone.0203309.ref028]\]. Therefore, the potential association between FVL and CVT in studies from the above countries should be confirmed in future studies. Moreover, although the results of subgroup analyses were statistically insignificant in some studies, we found the results of subgroup analyses were generally similar to the overall prevalence of FVL. In addition, the results of subgroup analysis based on the CVT ascertainment showed that the prevalence of FVL was higher in studies in which CVT was diagnosed by specific radiological methods, but not in studies that included documented CVT. These analyses further confirmed the robustness of the results.

Our analysis had some strength as compared to previous reviews. In order to make our findings more robustness and credible, we applied several methods. First, in addition to electronic databases searches, we also conducted comprehensive manual-search of the reference lists of relevant reviews and tried our best to include all eligible studies. To date, our meta-analysis has the largest sample size to confirm the prevalence of FVL in CVT. In addition, this is also the first meta-analysis for geographical variation of FVL in patients with CVT and suggests that the prevalence of FVL varies from country to country. Second, all the included studies were of moderate to high quality as evaluated by NOS, which made the extracted data more reliable. Third, we performed sensitivity and subgroup analyses to identify the source of heterogeneity and ensure the stability of the results. Finally, we attempted to minimize publication bias by manually searching for abstracts and letters, and excluding studies with considerable population overlap (\>50%), and no significant publication bias was detected by funnel plot or the Egger's test.

However, there were some limitations that should be noted when interpreting the results. First, the balance of baseline characteristics of CVT cases and controls varied in the included studies. Not all studies matched participants for age and sex, which likely introduced a certain degree of heterogeneity. We attempted to overcome this limitation by performing subgroup analysis and the results were generally similar to the overall results. Second, we were unable to extract data for adults or children separately due to a broad age range of population in most of the studies. Therefore, our analysis failed to adequately control for age and included adults and children of all ancestries. However, we conducted a sensitivity analysis for the overall results, which showed good stability. Third, we did not distinguish between provoked and unprovoked thrombotic factors for CVT as we were unable to obtain these data. Finally, our subgroup analysis according to countries did not take into account different ethnicities within a country, which may make the interpretation of the results difficult.

In conclusion, our meta-analysis confirmed a significant association between FVL and CVT. However, this association was highly dependent on the geography of origin. More studies are warranted to evaluate the prevalence of FVL in unprovoked or provoked CVT. Moreover, the potential role of FVL as a predictor of recurrent CVT also deserves further evaluation.
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